New statement: Patients with PIDs should have access to safe, efficacious and high-quality immunoglobulin therapies

Immunoglobulin therapies are life-saving products for patients with PIDs and many other conditions. It is therefore crucial that these essential medicines follow stringent manufacturing processes and a solid regulatory oversight that takes into account and uses well-established regulatory principles to ensure that they are safe, efficacious and of good quality for the patients they are meant to treat.

IPOPI has released this position statement to support the efforts of its national PID patient organisations around the globe in requesting access to safe, efficacious and high-quality immunoglobulin therapies. Some of whom have been facing worrying developments in their countries pertaining to the distribution of sub-optimal immunoglobulin therapies that do not meet regulatory requirements and international standards.

Read the full statement here